Sun Pharma Advanced Research Company (SPARC) has out-licensed Xelpros to a subsidiary of Sun Pharma for the US market

Sun Pharma Advanced Research Company (SPARC) has out-licensed Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the US market.

As per publication in Economic Times , In addition to up-front payment of USD 3 million, will receive certain other milestone payments, both totaling to USD 16 million from Sun Pharma.

The in-licensing of Xelpros will facilitate Sun Pharma’s entry into the branded Ophthalmology segment in the US. This is a part of Sun Pharma’s strategy to strengthen its presence in the US specialty segment.